ArticleTobacco induced diseases2026
Circulating proteins as key genetically proxied mediators in the pathway from smoking to intracranial aneurysm disease: A mediation Mendelian randomization analysis.
Article in Tobacco induced diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe molecular mechanisms linking smoking to intracranial aneurysmal disease remain elusive. In this study, we aimed to employ Mendelian randomization (MR) analysis to identify proteomic pathways that mediate this relationship.
methodsWe conducted a two-step, two-sample MR study using summary-level GWAS data from the GSCAN (GWAS & Sequencing Consortium of Alcohol and Nicotine Use, release up to 2019) and the FinnGen study (release R12, 2024). In the first step, we estimated the effects of genetically proxied smoking, using the Lifetime Smoking Index (LSI) as the primary exposure, on circulating protein levels. In the second step, we assessed the associations of smoking-related proteins with the risk of unruptured intracranial aneurysms (uIAs) and aneurysmal subarachnoid hemorrhage (aSAH). Proteins that showed significant associations in both steps were considered potential mediators, and we calculated their mediation proportions using the product-of-coefficients method.
resultsGenetically proxied smoking was associated with increased risks of uIAs and aSAH. Each one standard deviation increase in LSI was associated with a 2.99-fold higher risk of uIAs (OR=2.99; 95% CI: 1.77-5.06) and a 2.51-fold higher risk of aSAH (OR=2.51; 95% CI: 1.72-3.66). After multiple-testing correction, LSI was causally associated with 427 circulating proteins; 22 correlated with aSAH and 22 with uIAs, with eight shared. Mediation analysis confirmed six mediators (CD74, HEG1, YAP1, FGF23, SFRP1, PGF) for the LSI-aSAH pathway and four (CD74, YAP1, ANGPT2, RTN4R) for the LSI-uIA pathway. CD74 and YAP1 were shared mediators with the highest mediation ratios.
conclusionsEight distinct circulating proteins mediate smoking-induced intracranial aneurysm development and rupture via independent biological cascades. CD74 and YAP1 may serve as priority candidate mediators for future mechanistic and translational investigations aimed at refining risk stratification in smoking-related intracranial aneurysms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.